{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=83", "query": { "intervention": "Control Capsules", "page": 83 }, "page_size": 10 }, "pagination": { "page": 83, "page_size": 10, "total_count": 2908, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=84&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=82&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T13:54:01.065Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT07115056", "title": "Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "ACL Injury", "ACL Tears", "ACL Surgery" ], "interventions": [ { "name": "Tranexamic Acid (TXA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Campbell Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "14 Years to 22 Years" }, "enrollment_count": 0, "start_date": "2026-04-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 6, "location_summary": "Evanston, Illinois • Chesterfield, Missouri • Durham, North Carolina + 3 more", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "Chesterfield", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115056" }, { "nct_id": "NCT04317807", "title": "R33: Levetiracetam in Early Psychosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early Psychosis" ], "interventions": [ { "name": "Levetiracetam Pill", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "16 Years to 40 Years" }, "enrollment_count": 65, "start_date": "2020-08-27", "completion_date": "2025-04-10", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317807" }, { "nct_id": "NCT04977388", "title": "NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Menkes Disease", "Occipital Horn Syndrome" ], "interventions": [ { "name": "Droxidopa", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Stephen G. Kaler, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 3, "start_date": "2021-07-12", "completion_date": "2024-06-29", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04977388" }, { "nct_id": "NCT03569631", "title": "A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome", "FXS", "Fra(X) Syndrome" ], "interventions": [ { "name": "BPN14770", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tetra Discovery Partners", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 30, "start_date": "2018-07-09", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2024-12-19", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03569631" }, { "nct_id": "NCT06334419", "title": "Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile X Syndrome" ], "interventions": [ { "name": "Gaboxadol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Craig Erickson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "MALE", "summary": "18 Years to 40 Years · Male only" }, "enrollment_count": 10, "start_date": "2024-01-29", "completion_date": "2025-06-24", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06334419" }, { "nct_id": "NCT05743244", "title": "Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Abrocitinib 200 MG Oral Tablet", "type": "DRUG" }, { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "12 Years to 35 Years" }, "enrollment_count": 78, "start_date": "2023-10-19", "completion_date": "2027-10-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 23, "location_summary": "Orange, California • Palo Alto, California • San Francisco, California + 20 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743244" }, { "nct_id": "NCT03865992", "title": "Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Joint Pain" ], "interventions": [ { "name": "Curcumin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Nanoemulsion", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 42, "start_date": "2019-04-30", "completion_date": "2027-08-04", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 4, "location_summary": "Duarte, California • Rancho Cucamonga, California • South Pasadena, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03865992" }, { "nct_id": "NCT03606057", "title": "A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-64565111", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "JNJ-64565111-matching Placebo", "type": "DRUG" }, { "name": "Moxifloxacin-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 188, "start_date": "2018-07-13", "completion_date": "2019-02-28", "has_results": false, "last_update_posted_date": "2020-03-03", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606057" }, { "nct_id": "NCT04083339", "title": "Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Cardiomyopathies" ], "interventions": [ { "name": "AT-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Applied Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 675, "start_date": "2019-09-20", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-11-04T13:54:01.065Z", "location_count": 28, "location_summary": "Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Lincoln", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083339" } ] }